SCHEMBL30401205

SCHEMBL30401205

COCc1cccc(Cn2cc(-c3cc(-c4cccc(C(C)(C)O)c4)nc(N)n3)nn2)n1

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 13/20 0.51
▸ ADORA2B P29275 10/20 0.51
▸ ADORA1 P30542 1/20 0.51
▸ GPR55 Q9Y2T6 1/20 0.41
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CD74 P04233 1/20 0.36
▸ MIF P14174 1/20 0.36
▸ KDR P35968 3/20 0.36
▸ FGFR3 P22607 1/20 0.36
▸ TEK Q02763 2/20 0.35
▸ EPHB4 P54760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20416663 1.00 ADORA2A (0.51) ADORA2AADORA2BADORA1GPR55MEN1
SCHEMBL20401454 0.90 GPR55 (0.53) ADORA2AADORA2BADORA1GPR55MEN1
SCHEMBL30401467 0.90 GPR55 (0.53) ADORA2AADORA2BADORA1GPR55MEN1
SCHEMBL20436386 0.90 ADORA2A (0.55) ADORA2AADORA2BADORA1GPR55MEN1
SCHEMBL20442127 0.87 TEK (0.47) ADORA2AADORA2BADORA1CD74MIF
SCHEMBL20417191 0.86 ADORA2A (0.46) ADORA2AADORA2BADORA1MEN1KMT2A
SCHEMBL30401143 0.86 ADORA2A (0.46) ADORA2AADORA2BADORA1KDRTEK
SCHEMBL30401930 0.86 ADORA2A (0.46) ADORA2AADORA2BADORA1GPR55CD74
SCHEMBL20401210 0.86 ADORA2A (0.46) ADORA2AADORA2BADORA1GPR55CD74
SCHEMBL20401029 0.86 ADORA2A (0.46) ADORA2AADORA2BADORA1KDRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116768859-A Azolopyrimidines for the treatment of cancer related disorders 艾库斯生物科学有限公司 2023-09-19 — — CN disclosed
CN-110214012-B Azolopyrimidines for the treatment of cancer related disorders 艾库斯生物科学有限公司 2023-05-09 — — CN disclosed
Send feedback